Latest Insider Transactions at Chinook Therapeutics, Inc. (KDNY)
This section provides a real-time view of insider transactions for Chinook Therapeutics, Inc. (KDNY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CHINOOK THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CHINOOK THERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 22
2022
|
Davis Jerel Director |
BUY
Other acquisition or disposition
|
Direct |
1,646
+0.22%
|
-
|
|
Dec 22
2022
|
Davis Jerel Director |
SELL
Other acquisition or disposition
|
Indirect |
482,767
-53.57%
|
-
|
|
Dec 22
2022
|
Davis Jerel Director |
BUY
Other acquisition or disposition
|
Indirect |
9,465
+44.13%
|
-
|
|
Dec 14
2022
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+9.94%
|
$0
$0.35 P/Share
|
|
Dec 13
2022
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-6.5%
|
$250,000
$25.0 P/Share
|
|
Dec 13
2022
|
Tom Frohlich Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.1%
|
$0
$0.42 P/Share
|
|
Dec 01
2022
|
Eric Bjerkholt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,770
-14.94%
|
$126,940
$22.29 P/Share
|
|
Dec 01
2022
|
Eric Dobmeier President, CEO |
SELL
Open market or private sale
|
Direct |
30,000
-11.04%
|
$660,000
$22.31 P/Share
|
|
Dec 01
2022
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+18.09%
|
$0
$0.42 P/Share
|
|
Dec 01
2022
|
Eric Dobmeier President, CEO |
SELL
Bona fide gift
|
Direct |
25,000
-10.56%
|
-
|
|
Nov 30
2022
|
Eric Bjerkholt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,414
+29.83%
|
-
|
|
Nov 07
2022
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-6.5%
|
$220,000
$22.16 P/Share
|
|
Nov 07
2022
|
Tom Frohlich Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+6.1%
|
$0
$0.42 P/Share
|
|
Oct 06
2022
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,360
-4.87%
|
$139,840
$19.69 P/Share
|
|
Oct 06
2022
|
Tom Frohlich Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,582
+8.24%
|
-
|
|
Oct 06
2022
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,796
+11.51%
|
-
|
|
Oct 06
2022
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,557
-22.16%
|
$67,583
$19.69 P/Share
|
|
Oct 06
2022
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,152
+38.75%
|
-
|
|
Sep 12
2022
|
Davis Jerel Director |
SELL
Other acquisition or disposition
|
Indirect |
974,918
-59.76%
|
-
|
|
Sep 12
2022
|
Davis Jerel Director |
BUY
Other acquisition or disposition
|
Indirect |
28,313
+47.07%
|
-
|
|
Sep 12
2022
|
Davis Jerel Director |
BUY
Other acquisition or disposition
|
Direct |
3,291
+0.22%
|
-
|
|
Sep 02
2022
|
Dolca Thomas Director |
BUY
Open market or private purchase
|
Direct |
10,000
+26.46%
|
$210,000
$21.21 P/Share
|
|
Aug 12
2022
|
Davis Jerel Director |
BUY
Other acquisition or disposition
|
Direct |
1,646
+0.22%
|
-
|
|
Aug 12
2022
|
Davis Jerel Director |
SELL
Other acquisition or disposition
|
Indirect |
482,768
-46.42%
|
-
|
|
Aug 12
2022
|
Davis Jerel Director |
BUY
Other acquisition or disposition
|
Indirect |
9,466
+44.13%
|
-
|
|
Aug 04
2022
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-45.88%
|
$100,000
$20.0 P/Share
|
|
Aug 04
2022
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+31.45%
|
$0
$0.35 P/Share
|
|
Jul 11
2022
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-45.88%
|
$90,000
$18.09 P/Share
|
|
Jul 11
2022
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+31.45%
|
$0
$0.35 P/Share
|
|
May 27
2022
|
Srinivas Akkaraju Director |
BUY
Open market or private purchase
|
Indirect |
570,000
+9.94%
|
$7,980,000
$14.0 P/Share
|
|
May 25
2022
|
Eric Dobmeier President, CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+2.37%
|
$65,000
$13.03 P/Share
|
|
Apr 11
2022
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-45.88%
|
$75,000
$15.36 P/Share
|
|
Apr 11
2022
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+31.45%
|
$0
$0.35 P/Share
|
|
Apr 04
2022
|
Davis Jerel Director |
SELL
Other acquisition or disposition
|
Indirect |
735,873
-73.2%
|
-
|
|
Apr 04
2022
|
Davis Jerel Director |
BUY
Other acquisition or disposition
|
Indirect |
25,920
+50.0%
|
-
|
|
Apr 04
2022
|
Davis Jerel Director |
BUY
Other acquisition or disposition
|
Direct |
2,468
+0.34%
|
-
|
|
Apr 04
2022
|
Versant Venture Capital Vii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
25,920
-100.0%
|
-
|
|
Apr 04
2022
|
Versant Venture Capital Vii, L.P. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
25,920
+50.0%
|
-
|
|
Apr 04
2022
|
Versant Venture Capital Vii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
709,953
-19.6%
|
-
|
|
Feb 18
2022
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-29.77%
|
$32,500
$13.0 P/Share
|
|
Feb 11
2022
|
Tom Frohlich Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,735
-2.64%
|
$44,820
$12.74 P/Share
|
|
Feb 11
2022
|
Alan Glicklich Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,391
-23.25%
|
$28,692
$12.74 P/Share
|
|
Feb 11
2022
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,498
-22.93%
|
$29,976
$12.74 P/Share
|
|
Feb 11
2022
|
Eric Bjerkholt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
895
-3.87%
|
$10,740
$12.74 P/Share
|
|
Feb 10
2022
|
Tom Frohlich Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,801
+4.59%
|
-
|
|
Feb 10
2022
|
Eric Dobmeier President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,247
+9.16%
|
-
|
|
Feb 10
2022
|
Alan Glicklich Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,668
+35.54%
|
-
|
|
Feb 10
2022
|
Andrew James King Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,301
+32.96%
|
$0
$0.35 P/Share
|
|
Feb 10
2022
|
Eric Bjerkholt Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,434
+9.53%
|
-
|
|
Feb 10
2022
|
Andrew James King Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,500
-37.91%
|
$32,500
$13.31 P/Share
|